XRAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DENTSPLY SIRONA Inc (XRAY) is not a strong buy for a long-term beginner investor at this moment. The stock shows mixed signals with weak financial performance, neutral technical indicators, and a lack of positive catalysts. Analysts have a cautious outlook, and there are no strong trading signals or recent influential trades to support a buy decision.
The MACD is positive but contracting, RSI is neutral at 41.172, and moving averages are converging. The stock is trading near its support level (S1: 11.652), but there is no clear bullish trend. The pre-market price of $12.13 is slightly above the pivot level of 12.229, indicating limited upward momentum.
NULL identified. No recent news or significant positive developments.
Analysts have lowered price targets, with Citi initiating a Sell rating and a $10 price target. Weak macroeconomic conditions are expected to pressure the dental sector, and competition is eroding pricing power. Financial performance is poor, with declining net income, EPS, and gross margin.
In Q4 2025, revenue increased by 6.19% YoY to $961 million. However, net income dropped by 66.05% YoY to -$146 million, EPS fell by 66.20% YoY to -0.73, and gross margin declined by 8.31% to 46.1%.
Analysts are mixed but leaning negative. Citi initiated a Sell rating with a $10 price target. Evercore ISI lowered its price target to $13 from $15, maintaining an In Line rating. UBS and BofA have Buy ratings with price targets of $16-$17, but these are based on medium-term growth stabilization rather than immediate upside.
